CXCR2 and neoplasm: Our studies have demonstrated that anti-PD-1 antibody immunotherapy promotes the recruitment of granulocytic myeloid-derived suppressor cells (Gr-MDSCs) to the tumor bed in a CXCR2-dependent manner.